Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.17 USD
Change Today -0.01 / -0.09%
Volume 28.5K
LMNS On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

lumenis ltd - b (LMNS) Snapshot

Open
$11.06
Previous Close
$11.18
Day High
$11.37
Day Low
$11.06
52 Week High
04/2/15 - $12.45
52 Week Low
09/2/14 - $8.19
Market Cap
397.8M
Average Volume 10 Days
41.9K
EPS TTM
$0.43
Shares Outstanding
35.6M
EX-Date
--
P/E TM
25.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for LUMENIS LTD - B (LMNS)

Related News

No related news articles were found.

lumenis ltd - b (LMNS) Related Businessweek News

No Related Businessweek News Found

lumenis ltd - b (LMNS) Details

Lumenis Ltd., together with its subsidiaries, develops and commercializes energy-based medical systems for use in minimally invasive procedures worldwide. It operates through three segments: Surgical, Ophthalmic, and Aesthetic. The Surgical segment offers surgical laser systems and accessories used for urology/genitourinary and ENT to hospitals, outpatient clinics, ambulatory surgery centers, and medical practices. The Ophthalmic segment sells ophthalmology laser systems and accessories, such as laser links, slit lamp microscopes, laser indirect ophthalmoscopes, physician eye safety filters, surgical laser probes, and others to ophthalmic practices, outpatient clinics, and ophthalmology departments of hospitals primarily for use in retinal treatment and glaucoma/secondary cataract applications, as well as for refractive applications. The Aesthetic segment offers aesthetic laser energy-based systems to physicians primarily for skin treatment and hair removal applications. The company also provides technical training and certification of field service engineers and distributor service personnel; operates communications centers that perform installation, maintenance, and periodic and preventive servicing activities; publishes and controls the technical documentation, including service manuals and technical bulletins; and provides spare parts and logistics channels. It markets its products through a network of third-party distributors, direct sales force, and independent distributors. The company was formerly known as ESC Medical Systems Ltd. and changed its name to Lumenis Ltd. in September 2001. Lumenis Ltd. was founded in 1991 and is headquartered in Yokneam, Israel.

954 Employees
Last Reported Date: 04/2/15
Founded in 1991

lumenis ltd - b (LMNS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lumenis ltd - b (LMNS) Key Developments

Fosun In Talks Over Potential $480 Million Deal for Lumenis

Fosun International Limited (SEHK:656) is in talks to buy Lumenis Ltd. (NasdaqGS:LMNS) for nearly $500 million, financial newspaper Calcalist reported. Fosun has made initial contact with Lumenis and Lumenis would accept an offer of $480 million, 26% above its market value of $380 million, the newspaper said without identifying its sources. The newspaper noted that if the deal goes through, Fosun would look to merge Lumenis with Alma Lasers, Ltd. acquired by Fosun in 2013. A Fosun spokeswoman in Beijing and Lumenis Corporate Marketing Director Sigal Deutsch both said that their respective companies do not comment on market rumors.

Lumenis Ltd. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year Ended December 31, 2015

Lumenis Ltd. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company's total revenues were $77,232,000 compared to $71,094,000 a year ago. Operating income was $7,386,000 compared to $6,299,000 a year ago. Net loss was $6,820,000 compared to $4,702,000 a year ago. Diluted net income per common share was $0.19 compared to $0.18 a year ago. Net cash provided by operating activities was $6,935,000 compared to $6,116,000 a year ago. Purchase of property and equipment was $787,000 compared to $1,075,000 a year ago. Non GAAP operating income was $8,053,000 compared to $6,460,000 a year ago. Adjusted EBITDA (non- GAAP) was $9,726,000 compared to $7,888,000 a year ago. Non-GAAP net income was $7,062,000 compared to $5,457,000 a year ago. Non-GAAP diluted net income per common share was $0.20 compared to $0.18 a year ago. For the year, the company's total revenues were $289,719,000 compared to $265,356,000 a year ago. Operating income was $21,216,000 compared to $25,613,000 a year ago. Net loss was $12,725,000 compared to $17,393,000 a year ago. Diluted net income per common share was $0.36 compared to $0.58 a year ago. Net cash provided by operating activities was $12,492,000 compared to $29,387,000 a year ago. Purchase of property and equipment was $3,836,000 compared to $3,624,000 a year ago. Non GAAP operating income was $25,436,000 compared to $20,331,000 a year ago. Adjusted EBITDA (non- GAAP) was $32,430,000 compared to $26,003,000 a year ago. Non-GAAP net income was $19,922,000 compared to $14,886,000 a year ago. Non-GAAP diluted net income per common share was $0.57 compared to $0.50 a year ago. For the full year ended December 31, 2015, the company expects revenue in the range of $305 million to $310 million, representing growth of 5.3% to 7.0% year-over-year on a reported basis. Assuming current exchange rates, the company estimates the foreign currency translation negative impact on total reported revenues to be approximately $11 million. Excluding the impact of foreign currency translation, revenues are expected to increase 9.5% to 11.3% year-over-year. The company expects adjusted EBITDA in the range of $35 million to $37 million, representing growth of 7.9% to 14.1% year-over-year. Assuming current exchange rates, the company estimates that foreign currency translation negative impact on adjusted EBITDA to be approximately $5.0 million. Excluding the impact of foreign currency adjusted EBITDA is expected to increase 28.6% to 36.0% year-over-year. Non-GAAP EPS in the range of $0.62 to $0.66, representing growth of 9.1% to 16.1% year-over-year.

Lumenis Ltd., Q4 2014 Earnings Call, Feb 12, 2015

Lumenis Ltd., Q4 2014 Earnings Call, Feb 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMNS:US $11.17 USD -0.01

LMNS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LMNS.
View Industry Companies
 

Industry Analysis

LMNS

Industry Average

Valuation LMNS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMENIS LTD - B, please visit www.lumenis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.